All In Biotech

Drug Trial Radar · NCT05295732

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - With a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (X-linked) or ARCI Ichthyosis in Subjects Aged ≥6 Years

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

153

Actual

Start

Jun 21, 2022

Primary completion

Jun 17, 2024

Study completion Sep 23, 2024

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Mar 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind and vehicle-controlled Phase III study to evaluate the safety and efficacy of topical TMB-001 0.05% ointment for the treatment of congenital ichthyosis (CI) in subjects with either the RXLI or ARCI subtypes. In addition, a subset of preselected centers will recruit subjects in parallel with either the RXLI or ARCI subtypes for enrollment into an Optional Maximal Use arm for evaluation of the systemic exposure and safety of topical TMB-001 0.05% ointment for the treatment of CI. The Phase III Study is designed in three periods: \- Period 1 - Induction (3 weeks): At the beginning of the 3-week Induction Period, eligible subjects will be randomized (2:1 ratio) to either TMB-001 0.05% once-a-day (QD) or Vehicle QD treatment, with use of mandatory standardized bland emollient (Cetaphil™) provided by the Sponsor. \- Period 2 - Treatment (9 weeks): The dosing frequency in the 9-week treatment period will be increased in each treatment group to TMB-001 0.05% BID or Vehicle BID. Mandatory bland emollient will be discontinued. \- Period 3 - Maintenance (12 weeks): At Week 12, eligible subjects in the TMB-001 treatment group will be randomized (1:1 ratio) to an open-label treatment with TMB-001 0.05% BID or TMB-001 0.05% QD. To be eligible, subjects must have achieved a ≥1-point reduction in IGA score from Baseline. Subjects with less than a 1-point reduction in IGA score from Baseline will be discontinued from the study. Vehicle-treated subjects who achieved \<1-point reduction in IGA score from Baseline are eligible to cross over to the TMB-001 0.05% BID treatment group. Subjects with a ≥1-point reduction in IGA score from Baseline on vehicle will be discontinued from the study. Subjects at the end of the study or subjects discontinued from the study at any time will be followed-up for additional 2 weeks for AEs.

Conditions

  • Ichthyosis

Interventions

  • TMB-001Drug

    Topical TMB-001 0.05% QD/BID

  • Matching VehicleDrug

    Topical Vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Investigator Global Assessment (IGA) ScoreTime frame: 12 weeks

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • U.S. Dermatology Partners

    Phoenix, Arizona

  • Stanford University School of Medicine

    Palo Alto, California

  • About Skin Dermatology

    Centennial, Colorado

  • Yale Center for Clinical Investigation

    New Haven, Connecticut

  • Department of Dermatology and Cutaneous Surgery, University of Miami

    Miami, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • The Indiana Clinical Trials Center

    Plainfield, Indiana

  • Associated Skincare Specialists

    New Brighton, Minnesota

  • University of Mississippi Medical Center (UMMC)

    Jackson, Mississippi

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Optima Research

    Boardman, Ohio

  • Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Austin Institute for Clinical Research

    Houston, Texas

  • Austin Institute for Clinical Research, Inc.

    Pflugerville, Texas

  • Virginia Clinical Research-Pariser Dermatology Specialists

    Norfolk, Virginia

  • North Sound Dermatology

    Mill Creek, Washington

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • Dr. Chih-ho Hong Medical Inc.

    Surrey, British Columbia, Canada

  • Wiseman Dermatology Research Inc.

    Winnipeg, Manitoba, Canada

  • SickKids Hospital

    Toronto, Ontario, Canada

  • Hôpital Femme Mère Enfant

    Bron, France

  • CHU de Nantes Hotel Dieu

    Nantes, France

  • Hopital Necker APHP

    Paris, France

  • Hopital Larrey CHU Toulouse

    Toulouse, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Katholisches Kinderkrankenhaus Wilhelmstift GmbH

    Hamburg, Germany

  • Münster University Hospital

    Münster, Germany

  • U.O. di Dermatologia e Venereologia Universitaria

    Bari, Italy

  • U.O. di Dermatologia Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

    Bologna, Italy

  • Ambulatorio di Malattie Rare Dermatologiche e Immunopatologia Cutanea

    Florence, Italy

  • Fondazione IRCCS Ospedale Maggiore Policlinico Milano, Area Materno Infantile - SC pediatria Pneumoinfettivologia

    Milan, Italy

  • U.O.C. di Dermatologia Dipartimento Pediatrico Universitario Ospedaliero

    Roma, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.